Edgewise Therapeutics (Edgewise Therapeutics) Change In Working Capital : $-1.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Change In Working Capital?

Edgewise Therapeutics's change in working capital for the quarter that ended in Dec. 2023 was $-0.20 Mil.

Edgewise Therapeutics's change in working capital for the fiscal year that ended in Dec. 2023 was $-1.56 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Edgewise Therapeutics Change In Working Capital Historical Data

The historical data trend for Edgewise Therapeutics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Change In Working Capital Chart

Edgewise Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

0.33

1.95

4.63

4.09

-1.56

Edgewise Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial												5.49	-1.99	-0.34	0.97	-0.20

Edgewise Therapeutics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.56 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Edgewise Therapeutics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3415 Colorado Avenue, Boulder, CO, USA, 80303

Website

https://www.edgewisetx.com

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Executives

John R Moore	officer: General Counsel	3200 WALNUT ST, BOULDER CO 80301
Alan J Russell	director, officer: Chief Scientific Officer	3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan	officer: Chief Business Officer	3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch	director, officer: President and CEO	3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan	officer: CMO	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran	officer: Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017